Arca
Skip to content
Tools
Tools

Label Changes: Joenja (leniolisib phosphate)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Joenja label DailyMed has published, from Pharming Healthcare Inc., and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 5
  • Sections changed, version 6 to 8: 13

What changed from version 6 to version 8

Jun 12, 2025 to Oct 5, 2026, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. Indications and usageChanged · 8 words added, 1 removed
  2. Dosage and administrationChanged · 110 words added, 48 removed
  3. Dosage forms and strengthsChanged · 59 words added, 25 removed
  4. Warnings and precautionsChanged · 1 word added, 2 removed
  5. Adverse reactionsChanged · 268 words added, 40 removed
  6. Use in specific populationsChanged · 226 words added, 91 removed
  7. DescriptionChanged · 40 words added, 6 removed
  8. Clinical pharmacologyChanged · 89 words added, 2 removed
  9. Clinical studiesChanged · 8 words added, 4 removed
  10. How suppliedChanged · 114 words added, 45 removed
  11. Patient counseling informationChanged · 3 words added, 4 removed
  12. PRINCIPAL DISPLAY PANEL - 50 mg Tablet Bottle CartonNew section · 22 words added
  13. PRINCIPAL DISPLAY PANEL - 40 mg Tablet Bottle CartonNew section · 22 words added

Indications and usage

Changed8 words added, 1 removed
1 INDICATIONS AND USAGE
JOENJA is indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 124 years of age and older who weigh 27 kg or greater. (1)

Dosage and administration

Changed110 words added, 48 removed
3 unchanged lines
2.2 Recommended Dosage and Administration
The recommended dosage is based on weight as provided in Table 1.
Administer JOENJA orally twice daily approximately 12 hours apart, with or without food.
The recommended dosage of JOENJA in adult and pediatric patients 12 years of age and older weighing 45 kg or greater is 70 mg administered orally twice daily approximately 12 hours apart, with or without food. There is no recommended dosage for patients weighing less than 45 kg.
Table 1 Recommended Dosage of JOENJA in Adult and Pediatric Patients 4 Years of Age and Older Who Weigh 27 kg or Greater
Age | Patient's Body Weight | Recommended Oral Dosage
4 years to less than 12 years of age | 27 kg to less than 38 kg | 40 mg twice daily
38 kg to less than 45 kg | 50 mg twice daily
45 kg or greater | 70 mg twice daily
12 years of age and older | Any weight | 70 mg twice daily
Missed Dose(s)
Advise patients that if a dose is missed by more than 6 hours, wait and take the next dose at the usual time.
Advise patients that if vomiting occurs within 1 hour after taking JOENJA, take JOENJA as soon as possible. If vomiting occurs more than 1 hour after dosing, wait and take the next dose at the usual time.

Dosage forms and strengths

Changed59 words added, 25 removed
3 DOSAGE FORMS AND STRENGTHS
Tablets:
Tablets: 70 mg (leniolisib), yellow, oval-shaped, biconvex, bevelled edge film-coated tablet debossed with "70" on one side and "LNB" on the other side.
40 mg: Pink, round, biconvex, beveled edge tablet with 40 on one side and LNB on the other side
50 mg: Brownish red, round, biconvex, beveled edge tablet with 50 on one side and LNB on the other side
70 mg: Yellow, oval, biconvex, beveled edge tablet with 70 on one side and LNB on the other side

Warnings and precautions

Changed1 word added, 2 removed
1 unchanged line
5.1 Embryo-Fetal Toxicity
Based on findings in animals, JOENJA may cause fetal harm when administered to a pregnant woman. Administration of leniolisib to rats and rabbits during the period of organogenesis caused embryo-fetal toxicity including malformations at exposures that were 2-6 times higher than the maximum recommended human dose (MRHD) in APDS patients based on AUC comparisons. Verify the pregnancy status of patients of reproductive potential prior to starting treatment. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use highly effective methods of contraception during treatment and for 1 week after the last dose [see Dosage and Administration (2.1), Use in Specific Populations (8.1, 8.3)].
5.2 Vaccinations
1 unchanged line
5.3 Risk of Hypersensitivity Reactions, Including Anaphylaxis
Hypersensitivity reaction(s), including anaphylaxis, have been reported in the postmarketing setting. If a clinically significant hypersensitivity reaction occurs, discontinue JOENJA and institute appropriate therapy [see Adverse Reactions (6.2)].

Adverse reactions

Changed268 words added, 40 removed
4 unchanged lines
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adverse Reactions in Patients 12 Years of Age and Older with APDS
The safety of JOENJA reflects exposure based on 38 adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) from the placebo-controlled portion of Study 2201 [see Clinical Studies (14)] and additional open-label clinical safety data. Thirty-seven of 38 patients received JOENJA 70 mg orally twice daily for at least 25 weeks and 66% were exposed for 96 weeks or longer. Median duration of JOENJA treatment was approximately 2 years, and 4 patients had more than 5 years of JOENJA exposure.
The data below are based on the 12-week, placebo-controlled portion of Study 2201 in which either JOENJA 70 mg (N=21) or placebo (N=10) was administered twice daily to patients with APDS. Demographics of the patients who participated in this study are summarized in Clinical Studies [see Clinical Studies (14)]. Table 12 presents the number of patients and incidence, rounded to the nearest percent, of adverse reactions that occurred in 2 or more patients treated with JOENJA and for which the incidence in patients treated with JOENJA was greater than the incidence in patients treated with placebo.
The most common adverse reactions (> 10%) were headache, sinusitis, and atopic dermatitis.
Table 12 Adverse Reactions Reported by 2 or More JOENJA-Treated Adult and Pediatric Patients 12 Years of Age and Older and More Frequently than Placebo (Study 2201)
Adverse Reactions | JOENJA N=21 n (%) | Placebo N=10 n (%)
11 unchanged lines
Alopecia | 2 (10) | 0
Adverse Reactions in Pediatric Patients 4 Years to Less Than 12 Years of Age with APDS
The safety of JOENJA in pediatric patients 4 years to less than 12 years of age who weigh 27 kg or greater with APDS was based on 8 patients in a single-arm, open-label safety and pharmacokinetic study (Study LE3301) [see Clinical Pharmacology (12.3)]. Pediatric patients 4 years to less than 12 years of age received the recommended dosage of JOENJA based on body weight at baseline for at least 12 weeks and up to 24 weeks.
Adverse reactions reported in pediatric patients 4 years to less than 12 years of age were consistent with adverse reactions reported in adults and pediatric patients 12 years of age and older. Additional common adverse reactions reported in pediatric patients 4 years to less than 12 years of age who weigh 27 kg or greater (reported by 3 or more patients) were abdominal pain, cough, and respiratory tract infection.
Specific Adverse Reactions
Laboratory Abnormalities
Seven (33%) patients receiving JOENJA developed an absolute neutrophil count (ANC) between 500 and 1500 cells/microL. No patients developed an ANC < 500 cells/microL and there were no reports of infection associated with neutropenia.
Seven (33%) patients 12 years of age and older (n=21) and five (63%) patients 4 years to less than 12 years of age and weighing 27 kg or greater (n=8) developed an absolute neutrophil count (ANC) between 500 and 1500 cells/microL after receiving JOENJA. No patients developed an ANC < 500 cells/microL and there were no reports of infection associated with neutropenia.
Weight Increase
In the open-label clinical trial (n=37)study portion of Study 2201, five patients (14%) patients 12 years of age and older (n=37) experienced weight gain. Some patients became overweight or obese.
6.2 Postmarketing Experience
2 unchanged lines

Use in specific populations

Changed226 words added, 91 removed
24 unchanged lines
8.4 Pediatric Use
The safety and effectiveness of JOENJA for the treatment of activated phosphoinositide 3-kinase delta syndrome have been established in pediatric patients 12 years of age and older. Use of JOENJA for this indication is supported by evidence from an adequate and well-controlled study in adult and pediatric patients 12 years of age and older [see Clinical Studies (14)]. There is no recommended dosage for pediatric patients 12 years of age and older who weigh less than 45 kg [see Dosage and Administration (2.2)].
The safety and effectiveness of JOENJA for the treatment of activated phosphoinositide 3-kinase delta syndrome have been established in pediatric patients 4 years of age and older who weigh 27 kg or greater. Use of JOENJA for this indication is supported by evidence from an adequate and well-controlled study in adult and pediatric patients 12 years of age and older (Study 2201) [see Clinical Studies (14)], and safety and pharmacokinetic data from a single-arm, open-label study (Study LE 3301) in pediatric patients 4 years to less than 12 years of age. A total of 8 pediatric patients aged 4 to less than 12 years in Study LE3301 received the recommended dosage of JOENJA based on body weight. The pharmacokinetic data demonstrated no clinically significant difference between pediatric patients younger than 12 years of age and adult and pediatric patients 12 years of age and older [see Clinical Pharmacology (12.3)]. Safety of JOENJA in pediatric patients aged 4 years to less than 12 years were consistent with adult and pediatric patients aged 12 years and older. Additional adverse reactions reported in pediatric patients aged 4 years to less than 12 years who weigh 27 kg or greater were abdominal pain, cough, and respiratory tract infection [see Adverse Reactions (6.1)].
The safety and effectiveness of JOENJA have not been established in pediatric patients belowyounger thethan age4 years of 12age yearsor who weigh less than 27 kg.
Juvenile Animal Toxicity Data
5 unchanged lines

Description

Changed40 words added, 6 removed
4 unchanged lines
Leniolisib phosphate is a white to yellowish to yellowish-greenish powder. The aqueous solubility of leniolisib phosphate is pH dependent with decreasing solubility observed with increasing pH.
JOENJA film-coated tablets are for oral administration. Eachand tabletare containsavailable in 40 mg, 50 mg, and 70 mg strengths of leniolisib, (equivalent to 48.72 mg, 60.90 mg, and 85.26 mg leniolisib phosphate), withrespectively. The tablet core contains the following inactive ingredients: colloidal silicon dioxide, hydroxypropyl methylcellulose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium starch glycolate. The tablet filmcoatingfilm containscoating agents contain hydroxypropyl methylcellulose, iron oxide black (50 mg), iron oxide red (40 mg, 50 mg, and 70 mg), iron oxide yellow (70 mg), polyethylene glycol, talc, and titanium dioxide.

Clinical pharmacology

Changed89 words added, 2 removed
1 unchanged line
12.1 Mechanism of Action
Leniolisib inhibits PI3K-delta by blocking the active binding site of PI3K-delta. In cell-free isolated enzyme assays, leniolisib was selective for PI3K-delta over PI3K-alpha (28-fold), PI3K-beta (43-fold), and PI3K-gamma (257-fold), as well as the broader kinome. In cell-based assays, leniolisib reduced pAkt pathway activity and inhibited proliferation and activation of B and T cell subsets. Gain-of-function variants in the gene encoding the p110-delta catalytic subunit or loss of function variants in the gene encoding the p85-alpha regulatory subunit each cause hyperactivity of PI3K-delta. Leniolisib inhibits the signallingsignaling pathways that lead to increased production of PIP3, hyperactivity of the downstream mTOR/Akt pathway, and to the dysregulation of B and T cells.
12.2 Pharmacodynamics
Ex vivo pharmacodynamics of leniolisib [proportion of phosphorylated Akt (pAkt)-positive B cells] were assessed intra-individually at 10, 30, and 70 mg twice daily for 4 weeks at each dose level in adult patients with APDS (N=6). Within the explored dose range, higher leniolisib plasma concentrations were generally associated with higher reduction of pAkt-positive B cells and higher doses were associated with a slightly higher peak reduction as well as more sustained reduction. Treatment with JOENJA 70 mg twice a day at steady state is estimated to produce time-averaged reduction of pAkt-positive B cells by approximately 80%.
12.3 Pharmacokinetics
The systemic drug exposure (AUC and Cmax) of leniolisib increased dose proportionally within the studied range of doses (20 to 140 mg twice a day dosing and single doses of 10 to 400 mg) in healthy adult participants. During twice daily dosing approximately 12 hours apart, leniolisib accumulates approximately 1.4-fold (range of 1.0 to 2.2) in achieving steady-state, consistent with an effective half-life (t1/2) of approximately 7 hours. Steady state drug concentrations can be expected to be reached after approximately 2 to 3 days of JOENJA treatment. The pharmacokinetics of leniolisib are similar between healthy participants and APDS patients.
Absorption
In a placebo controlled, single and multiple ascending dose study in healthy adult participants, leniolisib median time to maximum plasma concentration (Tmax) occurred at about 1 hour postdose. Tmax appeared independent of dose and was not altered after multiple oral doses. Food is unlikely to have a clinically meaningful effect on the systemic exposure of leniolisib during JOENJA treatment.
Distribution
1 unchanged line
Elimination
The mean recovery of total 14C-radioactivity following a single oral dose of 70 mg 14C-leniolisib in adult males was 92.5% (67.0% and 25.5% recovered via feces and urine, respectively) 168 hours postdose. Unchanged leniolisib (6.32%) was the predominant drug-related material recovered in urine.
Metabolism
2 unchanged lines
Pediatric Patients
Following a single 70 mg oral dose of leniolisib in APDS patients, leniolisib systemic exposures were comparable between pediatric patients (12 to 17 years of age) and adults (≥ 18 years of age), with median Tmax (ranging from 1 to 5 hours) reached approximately 3 hours post-dose in patients 12 to 17 years of age. The observed difference in the median Tmax between pediatric patients (12 to 17 years of age) and adults (≥ 18 years of age) is not clinically relevant given the PK variability and comparable concentration-time profiles between the two age groups.
Body weight was identified as a significant covariate impacting the pharmacokinetics of leniolisib. In pediatric patients younger than 12 years of age who weigh 27 kg or greater at the recommended dosage based on body weight, observed leniolisib Cmin is within the range of Cmin values of adults and pediatric patients aged 12 years of age and older following oral administration of the recommended dosage of 70 mg twice a day.
Patients with Hepatic Impairment
The effect of hepatic impairment on the pharmacokinetics of leniolisib has not been evaluated. As leniolisib is metabolized to a large extent by the liver (60%), use of JOENJA is not recommended in patients with moderate to severe hepatic impairment [see Use in Specific Populations (8.6)].
Drug Interaction Studies
Strong CYP3A4 Inhibitors: Leniolisib-exposure was increased approximately 2-fold when administered with itraconazole (strong CYP3A4 inhibitor).
Moderate CYP3A4 Inhibitors: PhysiologicalPhysiologically based pharmacokinetic (PBPK) model-based simulations predicted a maximum increase of 75% in leniolisib AUC0-12 with erythromycin (moderate CYP3A4 inhibitor).
CYP3A4 Inducers: PBPK model-based simulations predicted a maximum decrease of 78% and 58% in leniolisib AUC0-12 with rifampin (strong CYP3A4 inducer) and efavirenz (moderate CYP3A4 inducer), respectively.
3 unchanged lines
BCRP, OATP1B1, and OATP1B3 substrates: When co-administered, leniolisib increased rosuvastatin (a substrate of BCRP, OATP1B1, and OATP1B3) systemic exposure by 2-fold.
Other Drugs: No clinically relevant differences in the systemic exposure of midazolam (CYP3A4 substrate), caffeine (CYP1A2 substrate), furosemide (a substrate of OAT1 and OAT3), and metformin (a substrate of MATE1, MATE2-K, and OCT2) were observed following concomitant use with leniolisib.

Clinical studies

Changed8 words added, 4 removed
14 CLINICAL STUDIES
The efficacy of JOENJA was evaluated in the placebo-controlled portion of Study 2201 (NCT02435173), a 12-week blinded, randomized, placebo-controlled study in adult and pediatric patients 12 years of age and older with confirmed APDS-associated genetic PI3Kδ mutation with a documented variant in either PIK3CD or PIK3R1. Baseline patient demographics are shown in Table 23.
Table 23 Baseline Demographic and Disease Characteristics in Patients with APDS (Study 2201)
Demographics and Disease Characteristics | JOENJA (N=21) | Placebo (N=10)
13 unchanged lines
Patients had nodal and/or extranodal lymphoproliferation, as measured by index nodal lesion selected by the Cheson methodology on CT or MRI and clinical findings and manifestations compatible with APDS (e.g., history of repeated oto-sino-pulmonary infections, organ dysfunction). Immunosuppressive medications or PI3Kδ inhibitors (selective or non-selective) were prohibited within 6 weeks of baseline (Day -1 and the visit prior to first study drug administration) and throughout the study. In addition, patients who had previous or concurrent B cell depleters (e.g., rituximab) within 6 months of baseline were excluded from the study, unless absolute B lymphocytes in the blood were normal. B cell depleters were prohibited throughout the study.
Thirty-one patients were randomized 2:1 to receive either JOENJA 70 mg (N=21) or placebo (N=10) twice a day for 12 weeks. The co-primary efficacy endpoints were improvement in lymphoproliferation as measured by a change from baseline in lymphadenopathy measured by the log10-transformed sum of product diameters and the normalization of immunophenotype as measured by the percentage of naïve B cells out of total B cells. Both co-primary efficacy endpoints were statistically significant (Table 34).
Table 34 Co-primary Endpoints in Placebo-Controlled Portion of Study 2201 at Week 12 (Day 85)
| JOENJA (N=21) | Placebo (N=10)
18 unchanged lines
p-value | | 0.0002
Figure 1 represents the co-primary endpoints grouped by age (12 years < 18 years of age vs ≥ 18 years of age).
Figure 1 Difference from Baseline in Log10 Transformed SPD of Index Lesions and Percentage of Naïve B Cells out of Total B Cells (Patients with < 48% of Naïve B Cells at Baseline) by Age Group (Study 2201)

How supplied

Changed114 words added, 45 removed
16 HOW SUPPLIED/STORAGE AND HANDLING
How Supplied
JOENJA (leniolisib) tablets are supplied in bottles with a child-resistant cap as provided in Table 5.
Table 5 JOENJA Tablets and Package Configuration
Strength | Tablet Description | Package Configuration | NDC
JOENJA is available in 70 mg tablet: yellow, oval-shaped, biconvex, bevelled edge film-coated tablet debossed with "70" on one side and "LNB" on the other side. It is supplied in bottles with a child-resistant cap of 60 tablets (NDC 71274-170-60).
40 mg | Pink, round, biconvex, beveled edge tablets with 40 on one side and LNB on the other side | Bottle of 60 tablets | 71274-140-60
50 mg | Brownish red, round, biconvex, beveled edge tablet with 50 on one side and LNB on the other side | Bottle of 60 tablets | 71274-150-60
70 mg | Yellow, oval, biconvex, beveled edge tablets with 70 on one side and LNB on the other side | Bottle of 60 tablets | 71274-170-60
Storage and Handling
Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Do not refrigerate.

Patient counseling information

Changed3 words added, 4 removed
1 unchanged line
Embryo-Fetal Toxicity
Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy. [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1, 8.3)].
Advise females of reproductive potential to use highly effective contraceptivecontraception during treatment with JOENJA and for 1 week after the last dose [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)].
Vaccinations
10 unchanged lines
JOENJA is a trademark of Pharming Intellectual Property B.V.
©20252026 Pharming Technologies B.V. All rights reserved.
AC2004703US-0850
640241

PRINCIPAL DISPLAY PANEL - 50 mg Tablet Bottle Carton

New section22 words added
PRINCIPAL DISPLAY PANEL - 50 mg Tablet Bottle Carton
NDC 71274-150-60 Rx Only
Joenja® (leniolisib) tablets
50 mg
Pharming®
60 Tablets

PRINCIPAL DISPLAY PANEL - 40 mg Tablet Bottle Carton

New section22 words added
PRINCIPAL DISPLAY PANEL - 40 mg Tablet Bottle Carton
NDC 71274-140-60 Rx Only
Joenja® (leniolisib) tablets
40 mg
Pharming®
60 Tablets

Unchanged: Contraindications, Drug interactions, Overdosage, Nonclinical toxicology, PRINCIPAL DISPLAY PANEL - 70 mg Tablet Bottle Carton.

Every version

5 versions of set eefbcef8-2130-4654-8f29-b58077e08212, newest first.
VersionPublished on DailyMedCompareSPL file
8Oct 5, 2026Shown belowDownload .zip
6Jun 12, 2025With version 5Download .zip
5Oct 6, 2023With version 4Download .zip
4Apr 20, 2023With version 3Download .zip
3Apr 4, 2023First versionDownload .zip

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.